BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 336 filers reported holding BIO-TECHNE CORP in Q3 2019. The put-call ratio across all filers is 5.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $379,000 | -83.7% | 2,000 | -81.1% | 0.20% | -26.4% |
| Q4 2019 | $2,326,000 | +12.2% | 10,600 | 0.0% | 0.27% | +3.0% |
| Q3 2019 | $2,074,000 | -6.1% | 10,600 | 0.0% | 0.26% | +73.2% |
| Q2 2019 | $2,209,000 | -26.2% | 10,600 | -48.8% | 0.15% | -26.1% |
| Q4 2018 | $2,995,000 | -44.2% | 20,700 | -21.3% | 0.21% | -32.6% |
| Q3 2018 | $5,368,000 | +822.3% | 26,300 | +484.4% | 0.31% | +890.3% |
| Q4 2017 | $582,000 | -78.7% | 4,500 | -80.1% | 0.03% | -78.8% |
| Q3 2017 | $2,732,000 | -28.0% | 22,600 | -30.0% | 0.15% | -37.6% |
| Q2 2017 | $3,795,000 | +15.6% | 32,300 | 0.0% | 0.23% | +12.5% |
| Q1 2017 | $3,283,000 | -1.1% | 32,300 | 0.0% | 0.21% | -23.8% |
| Q4 2016 | $3,321,000 | -6.1% | 32,300 | 0.0% | 0.27% | -4.9% |
| Q3 2016 | $3,536,000 | +541.7% | 32,300 | +476.8% | 0.29% | +272.7% |
| Q2 2015 | $551,000 | -1.8% | 5,600 | 0.0% | 0.08% | -1.3% |
| Q1 2015 | $561,000 | +8.5% | 5,600 | 0.0% | 0.08% | -10.3% |
| Q4 2014 | $517,000 | – | 5,600 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |